Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,356 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene Expression Clear all
Completed No phase listed Observational

Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery

NCT00900016
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
protein expression analysis, western blotting, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 19, 2026, 3:32 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

NCT02179515
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Prostate Cancer, Tumors (Others), Ovarian Cancer
Interventions
MVA-brachyury- TRICOM
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 19, 2026, 3:32 PM EDT
Completed Early Phase 1 Interventional

NIH CCR2 AAA Study

NCT04586452
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA), No Abdominal Aortic Aneurysm (Non-AAA)
Interventions
AAA Group (Aim 3A), Non-AAA Group, Ex Vivo Human AAA Specimens (Aim 2A), Relationship between radiotracer and CCR2 (Aim 2B), AAA Group (Aim 3B-Reproducibility)
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 19, 2026, 3:32 PM EDT
Terminated Phase 2 Interventional Results available

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

NCT00918385
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nilutamide, Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 19, 2026, 3:32 PM EDT
Recruiting No phase listed Observational

The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis

NCT06323876
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HRCT, Blood Draw
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 101 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 19, 2026, 3:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler

NCT05620043
View directory record Official record
Conditions
Gene Expression
Interventions
Sculptra, Radiesse Plus
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 19, 2026, 3:32 PM EDT
Terminated Phase 3 Interventional Results available

Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer

NCT00863512
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel, gemcitabine hydrochloride, pemetrexed disodium, vinorelbine tartrate, standard follow-up care
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Burbank, California + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 19, 2026, 3:32 PM EDT
Not listed No phase listed Observational

Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules

NCT03309631
View directory record Official record
Conditions
Indeterminate Thyroid Cytology
Interventions
In vitro Diagnostic
Diagnostic Test
Lead sponsor
Pontificia Universidad Catolica de Chile
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Guntersville, Alabama • Palo Alto, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 19, 2026, 3:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage

NCT01143519
View directory record Official record
Conditions
HIV-1 Seropositive, Inflammation, Cancer, Cardiomyopathy
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 19, 2026, 3:32 PM EDT
Completed No phase listed Observational

Microarray Expression Profiling to Identify Stereotypic mRNA Profiles in Human Parturition

NCT00342277
View directory record Official record
Conditions
Preterm Birth, Premature Rupture of Membranes
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
6,838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 19, 2026, 3:32 PM EDT
Completed Not applicable Interventional

Pain Management Support Study for Patients With Advanced Cancer

NCT03432247
View directory record Official record
Conditions
Advanced Cancer
Interventions
Interactive Music Therapy, Verbal support
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 19, 2026, 3:32 PM EDT
Withdrawn Phase 2 Interventional

Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens

NCT01275274
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Retinoic acid, Standard of care
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 19, 2026, 3:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Bariatric Surgery on Adipocyte Metabolism

NCT04242524
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Circadian Clock Alignment, Circadian Clock Control
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 19, 2026, 3:32 PM EDT
Terminated Phase 2 Interventional Results available

Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

NCT00450385
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Vincristine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
5
States / cities
Stanford, California • Miami, Florida • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 19, 2026, 3:32 PM EDT
Completed Phase 1 Interventional Results available

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

NCT04034238
View directory record Official record
Conditions
Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
Interventions
LMB-100, Tofacitinib, Mesothelin Expression
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 19, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

NCT01536743
View directory record Official record
Conditions
Ovarian Epithelial Carcinoma
Interventions
PD0332991
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 19, 2026, 3:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Human Intracranial Electrophysiology

NCT05529264
View directory record Official record
Conditions
Epilepsy
Interventions
Memory Tasks, Attention/arousal tasks, Language tasks, Visuospatial tasks, Auditory Tasks, Brain Stimulation, Social Emotional Task, Recording of facial expressions, Judgement/Impulsivity Task
Other · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2032
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 19, 2026, 3:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Validation of the Ameda Pearl - An Electric, Hospital Grade, Multi-User Breast Pump

NCT05297799
View directory record Official record
Conditions
Breast Pumping
Interventions
Ameda Pearl breast pump
Device
Lead sponsor
Ameda, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 19, 2026, 3:32 PM EDT
Completed No phase listed Observational

Genetic and Protein Profiling in Normal and Cancerous Breast Tissue

NCT00083733
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 3:32 PM EDT
Completed No phase listed Observational

Immunoscore in Rectal Cancer

NCT02017509
View directory record Official record
Conditions
Cancer of the Rectum, Neoplasms, Rectal, Rectal Cancer, Rectal Tumors, Rectal Adenocarcinoma
Interventions
Diagnostic Biopsy and Surgical Procedure, Intravoxel incoherent motion MRI (IVIM), Dynamic Contrast Enhanced MRI (DCE-MRI), RNA gene expression analysis
Procedure · Genetic
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 19, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea

NCT03194698
View directory record Official record
Conditions
Ocular Rosacea, Dry Eye
Interventions
Intense Pulsed Light Treatment (IPL), Meibomian Gland Expression
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 19, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

NCT00466687
View directory record Official record
Conditions
Melanoma
Interventions
bevacizumab, erlotinib hydrochloride, fluorescence in situ hybridization, gene expression analysis, immunologic technique, laboratory biomarker analysis, biopsy
Biological · Drug · Genetic + 2 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 19, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids

NCT01222091
View directory record Official record
Conditions
Hyperalgesia
Interventions
Propranolol, Placebo to Match Propranolol, Remifentanil
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 19, 2026, 3:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

NCT02955290
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 19, 2026, 3:32 PM EDT